Swedish pharmaceutical company Camurus (STO:CAMX) announced on Thursday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa, octreotide subcutaneous depot, for maintenance treatment in adult patients with acromegaly, a rare, progressive disease, typically caused by a tumour of the pituitary gland, who have responded to and tolerated treatment with somatostatin analogues.
The MHRA's marketing authorisation for Oczyesa is based on the results from a comprehensive clinical programme which comprised seven clinical studies.
Oczyesa is formulated using Camurus' proprietary FluidCrystal technology. It is designed for convenient once-monthly, subcutaneous self-administration using a pre-filled autoinjector pen with a hidden, thin needle.
Oczyesa was granted marketing authorisation in the European Union by the European Commission on 30 June 2025.
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
BeOne Medicines reports positive topline data for sonrotoclax in mantle cell lymphoma
Cinclus Pharma to launch Phase III trial of linaprazan glurate in erosive GERD
Camurus' Oczyesa receives UK regulatory approval to treat acromegaly
Piramal Pharma supports George Medicines' development of hypertension drug WIDAPLIK
Foresee Pharmaceuticals reports US FDA approval of CAMCEVI ETM in advanced prostate cancer
Biophytis secures EMA and Belgian approval to launch Phase 3 sarcopenia trial
Airiver medical receives FDA approval for central airway stenosis trial
Cantargia secures US patent for nadunolimab combination therapies
European Commission approves Bio-Thera Solutions' BAT2206
INOVIO to begin rolling submission of BLA for INO-3107
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo